FDA approves 14‑month, all‑oral acalabrutinib plus venetoclax first-line for CLL/SLL, boosting progression-free survival and offering a fixed-duration alternative to chemo.
Andrea Eleazar, MHS
Andrea Eleazar, MHS is an assistant editor for Targeted Oncology, covering leukemias/lymphomas and topics in public health, health policy, & oncology practice.
Andrea holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Contact: aeleazar@targetedonc.com
Articles by Andrea Eleazar, MHS
Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.
FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.
ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.
Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.
Cancer breakthroughs surge, but trials and novel therapies stay out of reach for many. See how community care, policy, and design can close gaps.
FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.
G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment.
FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.
Final MOUNTAINEER data show tucatinib plus trastuzumab delivers durable responses and manageable safety in HER2+ RAS wild-type metastatic colorectal cancer.
SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable access barriers.
Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.
Community oncology delivers high-quality, lower-cost cancer care near home, but faces trial barriers, staff shortages, and rising complexity—driving AI-enabled, partnered transformation.
Phase 3 interim data show anbenitamab plus chemo boosts survival and response in previously treated HER2-positive gastric cancer with manageable toxicity.
Study finds income and other financial factors outweigh race in determining cancer trial enrollment, highlighting reforms and simpler trial designs to expand access.
CD34+ donor chimerism flags AML relapse early; timely donor lymphocyte infusion boosts MRD-negative remissions and survival after alloHSCT.
Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.
FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.
FDA reviews new drug applications for rivoceranib and camrelizumab as first-line treatments for advanced liver cancer, promising improved survival rates.
Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.
FDA reviews zanzalintinib and atezolizumab for metastatic colorectal cancer, offering hope for patients with limited treatment options.
FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.
Lirafugratinib shows promise as a second-line treatment for cholangiocarcinoma, achieving significant response rates and durable outcomes in clinical trials.
New trial data show onvansertib enhances treatment response and progression-free survival in RAS-mutated metastatic colorectal cancer, paving the way for future therapies.
FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.
A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.
The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.
Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.
New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.